Clinical trials
Hypertension trials in Thailand
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 8 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Recruiting | 4 |
| Not yet recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| DejthidaNathaphong | 4 |
| Mahidol University | 4 |
| Chiang Mai University | 3 |
| Khon Kaen University | 3 |
| Novartis Pharmaceuticals | 3 |
| Boehringer Ingelheim | 2 |
| Chulalongkorn University | 2 |
| Novartis | 2 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 44 |
| Diabetes Mellitus | 5 |
| Cardiovascular Diseases | 4 |
| Essential Hypertension | 4 |
| Stroke | 4 |
| Renal Insufficiency, Chronic | 3 |
| Coronary Artery Disease | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Hyperlipidemias | 2 |
| Kidney Diseases | 2 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.